Showing 1,460 news articles about Pharmaceutical industry

Filters Content type: Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Pharmaceutical industry

How a Drug Maker Profited by Slow-Walking a Promising H.I.V. Therapy

Editor's pick
The New York Times
23 July 2023
Access to healthcare

Open Letter: Community Statement on Accelerating Access to Lenacapavir by Gilead

Editor's pick
AfroCAB
18 July 2023
Access to healthcare

Major drug company bends in battle over access to key TB treatment

Editor's pick
Science
18 July 2023
HIV treatment for children & young people

Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries

Editor's pick
Gilead Sciences press release
14 July 2023
Pharmaceutical industry

Colombia to challenge AIDS drug patents

Editor's pick
Médecins Sans Frontières
13 July 2023
Pharmaceutical industry

HIV Drugmakers Gilead and Teva Didn’t Pay to Delay Drugs, Rules Jury

Editor's pick
POZ
4 July 2023
Sexually transmitted infections prevention

GSK receives US FDA Fast Track designation for investigational vaccine against gonorrhoea

Editor's pick
GlaxoSmithKline press release
28 June 2023
HIV treatment for children & young people

Innovative regulatory strategy drastically reduces time needed for new HIV drug to reach children

Editor's pick
Clinton Health Access Initiative
27 June 2023
Pharmaceutical industry

UNAIDS welcomes announcement by Colombian government that will enable people access to the most appropriate HIV treatment for them

Editor's pick
UNAIDS
14 June 2023
Testing & health monitoring

Access to point-of-care tests for people with advanced HIV under threat as diagnostics corporations to stop production

Editor's pick
Médecins Sans Frontières
15 May 2023
PrEP policies & guidelines

Statement from PrEP4All and PIPLI on the Disappointing Verdict in US v. Gilead

Editor's pick
PrEP4All
11 May 2023
Finance & funding

Gilead Wins Key Patent Rights Suit Over PrEP Drugs for Preventing HIV

Editor's pick
The New York Times
10 May 2023
Injectable & long-acting PrEP

The anti-HIV injection will be made in South Africa. It could cost between R600 and R800 a pop

Editor's pick
Bhekisisa
9 May 2023
Pharmaceutical industry

Feds Spent Even More on PrEP Combo Than Previously Thought

Editor's pick
MedPage Today
4 May 2023
Opportunistic infections

MSF calls on Gilead to finally fulfil access promise and make lifesaving drug for people with HIV available where needed

Editor's pick
MSF
4 May 2023
PrEP policies & guidelines

Gilead, US square off in billion-dollar HIV drug patent trial

Editor's pick
Reuters
2 May 2023
New & experimental HIV treatments

Merck reveals HIV combo trial is back in the running after FDA partial hold lifted 

Editor's pick
FierceBiotech
27 April 2023
New & experimental HIV treatments

GSK drops one of 2 maturation inhibitors in HIV pipeline

Editor's pick
FierceBiotech
27 April 2023
Pharmaceutical industry

EU pharma reform: Winners and losers

Editor's pick
Politico
27 April 2023
Injectable & long-acting PrEP

Pharmaceutical corporation ViiV must provide transparency on life-saving HIV-prevention drug

Editor's pick
Médecins Sans Frontières
31 March 2023
Injectable & long-acting PrEP

Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine

Editor's pick
Medicines Patent Pool
30 March 2023
Injectable & long-acting PrEP

Cabotegravir long-acting for PrEP registrations continue in Sub-Saharan Africa

Editor's pick
ViiV press release
29 March 2023
People with limited treatment options

WEP Clinical has partnered with TaiMed Biologics to launch a Trogarzo named patient program

Editor's pick
WEP Clinical press release
24 March 2023
Access to healthcare

MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug

Editor's pick
MSF
24 March 2023